2019 targeted radionuclide therapy consortjum
play

2019 Targeted Radionuclide Therapy Consortjum University of Wisconsin - PDF document

Feb 20, 2023 •148 likes •192 views

2019 Targeted Radionuclide Therapy Consortjum University of Wisconsin - Madison UW Memorial Union - Great Hall Friday, Sept 20 th - Sunday, Sept 22 nd , 2019 Contact Justjn Jefgery with questjons jjjefgery@wisc.edu TRTC 2019 Agenda Friday, Sept 20,

  1. 2019 Targeted Radionuclide Therapy Consortjum University of Wisconsin - Madison UW Memorial Union - Great Hall Friday, Sept 20 th - Sunday, Sept 22 nd , 2019 Contact Justjn Jefgery with questjons jjjefgery@wisc.edu

  2. TRTC 2019 Agenda Friday, Sept 20, 2019 - Memorial Union - Great Hall Introductjon & Social Event 3:00 - 4:00pm Registratjon 4:00 - 5:00pm Introductjon & Conference Overview 5:00 - 10:30pm Pyle Alumni Lounge/Pyle Roofuop Terrace Saturday, Sept 21, 2019 - Memorial Union - Great Hall Session 1: Radiochemistry, Isotopes & Supply ( Moderator: Reinier Hernandez, PhD) 7 - 7:30am Shutule to Memorial Union 7:30am Breakfast - Provided at the Memorial Union Jamey Weichert , PhD - University of Wisconsin 7:45 - 8am Introductjon and welcome 8 - 8:30am Jon Engle , PhD - University of Wisconsin 8:30 - 9am Scotu Wilbor , PhD - University of Washington 9 - 9:30am Cathy Cutler , PhD - Brookhaven Natjonal Laboratory 9:30 - 10am Break - Cofgee/Refreshments 10 - 10:30am Alejandro Amor , PhD - Albert Einstein College of Medicine 10:30 - 11am Gregory Severin , PhD - Michigan State University Session 2: Emerging Agents & Applicatjons (Moderator: Jacek Capala, PhD) 11 - 11:30am Frank Lin, MD - Natjonal Instjtutes of Health 11:30 - 12pm Steve Larson , MD - Memorial Sloan Ketuering Cancer Center 12 - 1pm Lunch - Provided at the Memorial Union

  3. TRTC 2019 Agenda 1 - 1:30pm Daniel Pryma , MD - University of Pennsylvania 1:30 - 2pm Michael Schultz , PhD - University of Iowa 2 - 2:30pm Lilja Bjork Solnes , MBA, MD - Johns Hopkins University 2:30 - 3pm Break - Cofgee/Refreshments 3 - 3:30pm Carolyn Anderson , PhD - University of Pitusburgh Rob Hobbs , PhD - Johns Hopkins University 3:30 - 4pm Frontjers in RPT Dosimetry: Small scale modeling and combinatjon therapies 4 - 4:30pm Zach Morris , MD, PhD - University of Wisconsin 5 - 10p Gala Dinner - Fresco (227 State St., Madison, WI 53703) Sunday, Sept 22, 2019 - Memorial Union - Great Hall Session 3: Imaging & Advanced Dosimetry (Moderator: Joseph Grudzinski, PhD) 7 - 7:30am Shutule to Memorial Union 7:30am Breakfast - Provided at the Memorial Union 8 - 8:30am Brian Miller , PhD - University of Colorado 8:30 - 9am Yuni Dewaraja , PhD - University of Michigan 9 - 9:30am Bryan Bednarz, PhD - University of Wisconsin 9:30 - 10am Break - Cofgee/Refreshments 10 - 10:30am Youngho Seo , PhD - University of California San Francisco 10:30 - 11am John Humm , PhD - Memorial Sloan Ketuering Cancer Center Imaging and Dosimetry of alpha - emittjng radionuclides

  4. Session 4: Clinical Translatjon, Regulatory & Reimbursement (Moderator: Yusuf Menda, MD) 11 - 11:30am Xiaoyuan (Shawn) Chen , PhD - Natjonal Instjtutes of Health 11:30 - 12pm David Bushnell , MD - University of Iowa 12 - 1pm Lunch - Provided at the Memorial Union Kellie Bodeker - University of Iowa 1 - 1:30pm Real regulatjons and consideratjons: combinatorial INDs, the single IRB mechanism, and pooling data from multjple sites 1:30 - 2pm Steve Cho , MD - University of Wisconsin 2 - 2:30pm Neeta Pandit - Taskar , MD - Memorial Sloan Ketuering Cancer Center 2:30 - 3pm Bonnie Clark - Society of Nuclear Medicine and Molecular Imaging 3 - 3:30pm Michael Graham , MD, PhD - University of Iowa Jamey Weichert , PhD - University of Wisconsin 3:30 Closing Remarks Sponsors

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Radioactive Synovectomy (RS) in Haemophilia Thynn Thynn Yee RS Local form of radionuclide

Radioactive Synovectomy (RS) in Haemophilia Thynn Thynn Yee RS Local form of radionuclide

Radioactive Synovectomy (RS) in Haemophilia Thynn Thynn Yee RS Local form of radionuclide therapy Removal of the synovial membrane by intra-articular application of radioisotopes RS therapy has been used in Rheumatoid Arthritis

521 views • 20 slides
IMAGE-BASED PATIENT-SPECIFIC DOSIMETRY FOR RADIONUCLIDE THERAPY Michael Ljungberg, PhD,

IMAGE-BASED PATIENT-SPECIFIC DOSIMETRY FOR RADIONUCLIDE THERAPY Michael Ljungberg, PhD,

IMAGE-BASED PATIENT-SPECIFIC DOSIMETRY FOR RADIONUCLIDE THERAPY Michael Ljungberg, PhD, Katarina Sjgreen-Gleisner, PhD International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry 9-12 November

755 views • 33 slides
Characterization Approaches for Radionuclide-Contaminated Radionuclide Contaminated Subsurface

Characterization Approaches for Radionuclide-Contaminated Radionuclide Contaminated Subsurface

Characterization Approaches for Radionuclide-Contaminated Radionuclide Contaminated Subsurface Sites MICHAEL TRUEX Pacific Northwest National Laboratory Outline Conceptual model framework Characterization for factors controlling fate and

385 views • 20 slides
Best Use of Osteoclast-Targeted Therapy Matthew R. Smith, M.D., Ph.D. Professor of Medicine,

Best Use of Osteoclast-Targeted Therapy Matthew R. Smith, M.D., Ph.D. Professor of Medicine,

Best Use of Osteoclast-Targeted Therapy Matthew R. Smith, M.D., Ph.D. Professor of Medicine, Harvard Medical School Director, Genitourinary Malignancies Program Massachusetts General Hospital Cancer Center Disclosures Personal financial

463 views • 18 slides
Will drugs targeted to genetic and epigenetic defects become the best future option in therapy of

Will drugs targeted to genetic and epigenetic defects become the best future option in therapy of

Will drugs targeted to genetic and epigenetic defects become the best future option in therapy of MPNs? Tiziano Barbui, MD Ospedali Riuniti di Bergamo-Italy 1st COHEM Congress Rome, Sunday, September 5, 2010 1 Two points for this debate: -

574 views • 16 slides
Is there a role for targeted therapy in the adjuvant or neoadjuvant setting? Nathan Pennell,

Is there a role for targeted therapy in the adjuvant or neoadjuvant setting? Nathan Pennell,

Is there a role for targeted therapy in the adjuvant or neoadjuvant setting? Nathan Pennell, M.D., Ph.D. February 11, 2017 44 Year Old Woman, Nonsmoker Presented in 2009 with RLL nodule, staging indicated likely stage IA adenocarcinoma

467 views • 21 slides
Occupational therapy with children: introduction to universal, targeted and specialist services

Occupational therapy with children: introduction to universal, targeted and specialist services

Occupational therapy with children: introduction to universal, targeted and specialist services Use this presentation with the course workbook 1 Disclaimer: All photographs are open access Learning Outcomes - 1 When you have completed this

291 views • 11 slides
neuroendocrine tumors Daa filigoj, Petra Tome, Luka Jensterle 13. maj, 2015 Department of

neuroendocrine tumors Daa filigoj, Petra Tome, Luka Jensterle 13. maj, 2015 Department of

Targeted radionuclide therapy of neuroendocrine tumors Daa filigoj, Petra Tome, Luka Jensterle 13. maj, 2015 Department of Nuclear Medicine University Medical Centre Ljubljana NETs heterogeneous group of tumors that frequently express

1.62k views • 34 slides
The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF

The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF

The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers Howard S Hochster, MD Distinguished Professor of Medicine Rutgers Robert Wood Johnson

238 views • 23 slides
Epigenetic Targeted Therapy in AML Martin S. Tallman, M.D. Chief, Leukemia Service Memorial

Epigenetic Targeted Therapy in AML Martin S. Tallman, M.D. Chief, Leukemia Service Memorial

Epigenetic Targeted Therapy in AML Martin S. Tallman, M.D. Chief, Leukemia Service Memorial Sloan Kettering cancer Center Professor of Medicine Weill Cornell Medical College New York, NY Acute Myeloid Leukemia State-of-the-Art 2017-2018

658 views • 48 slides
Molecular pathology of ameloblastoma: towards targeted therapy IAOP and AAOMP Joint Meeting

Molecular pathology of ameloblastoma: towards targeted therapy IAOP and AAOMP Joint Meeting

Molecular pathology of ameloblastoma: towards targeted therapy IAOP and AAOMP Joint Meeting June, 2018 Robert B. West, MD PhD Department of Pathology, Stanford University Medical Center 1. Discuss genomic differences between odontogenic

791 views • 47 slides
Radiation Toxicity in Era of Combined Modality Therapy with Targeted Agents Christopher J. Anker,

Radiation Toxicity in Era of Combined Modality Therapy with Targeted Agents Christopher J. Anker,

The heart and science of medicine. UVMHealth.org/CancerCenter Radiation Toxicity in Era of Combined Modality Therapy with Targeted Agents Christopher J. Anker, MD Assistant Professor Radiation Oncology University of Vermont Cancer Center October

663 views • 50 slides
Targeted Gene Therapy in the Treatment of X-linked Hyper-IgM Syndrome Caroline Kuo, MD Pediatric

Targeted Gene Therapy in the Treatment of X-linked Hyper-IgM Syndrome Caroline Kuo, MD Pediatric

Targeted Gene Therapy in the Treatment of X-linked Hyper-IgM Syndrome Caroline Kuo, MD Pediatric Allergy & Immunology Clinical Instructor 1 Disclosures None. Hyper-immunoglobulin M syndromes Heterogeneous group of genetic disorders

260 views • 21 slides
Adjuvant Therapy of Thyroid Cancer: rhTSH, RAI, EBRT and Targeted Therapeutics October 13, 2018

Adjuvant Therapy of Thyroid Cancer: rhTSH, RAI, EBRT and Targeted Therapeutics October 13, 2018

Adjuvant Therapy of Thyroid Cancer: rhTSH, RAI, EBRT and Targeted Therapeutics October 13, 2018 BC Cancer Surgeon Network Fall Update Jonn Wu BMSc MD FRCPC Radiation Oncologist, Vancouver Centre Chair, Provincial H&N Tumour Group, BCCA

961 views • 24 slides
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers, 15 December 2006 Cancer

498 views • 28 slides
WG 5: Radionuclide Transfer to wildlife EMRAS II Jan 2011 TRS: RADIONUCLIDE TRANSFER TO

WG 5: Radionuclide Transfer to wildlife EMRAS II Jan 2011 TRS: RADIONUCLIDE TRANSFER TO

EMRAS II WG 5: Radionuclide Transfer to wildlife EMRAS II Jan 2011 TRS: RADIONUCLIDE TRANSFER TO WILDLIFE EMRAS II Jan 2011 Activities Key output TRS on transfer to wildlife Core drafting group On-line database all

254 views • 13 slides
The Physics of Nuclei, Nuclear Matter and Nucleosynthesis Report of the Nuclear Physics Advisory

The Physics of Nuclei, Nuclear Matter and Nucleosynthesis Report of the Nuclear Physics Advisory

The Physics of Nuclei, Nuclear Matter and Nucleosynthesis Report of the Nuclear Physics Advisory Panel Advice to PPAN via the Nuclear Physics Advisory Panel Science Priorities Funding Facilities Projects What are the Origins of the Elements?

642 views • 14 slides
Activities of the OECD/ NEA In the Field of Decommissioning Patrick OSullivan NEA Secretariat

Activities of the OECD/ NEA In the Field of Decommissioning Patrick OSullivan NEA Secretariat

Activities of the OECD/ NEA In the Field of Decommissioning Patrick OSullivan NEA Secretariat Nordic Nuclear Safety Research (NKS) Seminar 14-16 September 2010 Nordic Nuclear Safety Research (NKS) Seminar: 14-16 September 2010 1 Plan of

642 views • 39 slides
Click to edit Margo Corsetti Mentor: Dr. Natasa Miskov-Zivanov DiSCoBio Acadamy Click to edit

Click to edit Margo Corsetti Mentor: Dr. Natasa Miskov-Zivanov DiSCoBio Acadamy Click to edit

Click to edit Margo Corsetti Mentor: Dr. Natasa Miskov-Zivanov DiSCoBio Acadamy Click to edit Chemotherapy & radiation: o Nonspecific o Continuous delivery Improvements: o Target disease sites only o Deliver treatment in an

561 views • 21 slides
FDA Presentation of PDUFA IV Recommendations Date Subjects Participants Time Length 1/11/07

FDA Presentation of PDUFA IV Recommendations Date Subjects Participants Time Length 1/11/07

FDA Presentation of PDUFA IV Recommendations Date Subjects Participants Time Length 1/11/07 Teleconference to brief on the Federal FDA: 12:00 NOON to Register notice of a public meeting to Theresa Mullin, OPPL 1:00 PM discuss the proposed

193 views • 3 slides
Operation and Maintenance of Water Supplies Presented to Clean and Safe Drinking Water Workshop

Operation and Maintenance of Water Supplies Presented to Clean and Safe Drinking Water Workshop

Operation and Maintenance of Water Supplies Presented to Clean and Safe Drinking Water Workshop Gander, Newfoundland Presented by George Powell, P. Eng. Senior Vice-President CH2M HILL MILL Canada Limited March 2001 Ask yourself this

565 views • 53 slides
Asia-Pacific Nuclear Governance Fragile, Fragmented but Fixable? 29 March 2017 Trevor Findlay

Asia-Pacific Nuclear Governance Fragile, Fragmented but Fixable? 29 March 2017 Trevor Findlay

Asia-Pacific Nuclear Governance Fragile, Fragmented but Fixable? 29 March 2017 Trevor Findlay School of Social & Poli:cal Sciences University of Melbourne Research funded by the Carnegie Corpora5on of New York Outline nuclear energy

454 views • 20 slides
Carlsbad Environmental Monitoring & Research Center History, Mission, and Status Report By

Carlsbad Environmental Monitoring & Research Center History, Mission, and Status Report By

Carlsbad Environmental Monitoring & Research Center History, Mission, and Status Report By Russell Hardy, Director New Mexico State University CEMRC History and Mission The CEMRC was created in 1991, through a grant from the U.S. DOE,

438 views • 33 slides
Assessing the impacts of hydraulic fracturing on soil and water quality in the Surat Basin,

Assessing the impacts of hydraulic fracturing on soil and water quality in the Surat Basin,

Assessing the impacts of hydraulic fracturing on soil and water quality in the Surat Basin, Queensland Simon Apte | Senior Principal Research Scientist Introduction Considerable public concern about the environmental impacts of hydraulic

466 views • 30 slides

More recommend